Virological suppression achieved with suboptimal adherence levels among South African children receiving boosted protease inhibitor-based antiretroviral therapy

Clin Infect Dis. 2009 Jan 1;48(1):e3-5. doi: 10.1086/595553.

Abstract

Sixty-six children who were receiving antiretroviral treatment were assessed for treatment adherence and virological outcome to compare boosted protease inhibitor-based regimens with nonnucleoside reverse-transcriptase inhibitor-based regimens. Children who were receiving protease inhibitor-based regimens demonstrated higher rates of virological suppression, even with poor treatment adherence (<80%). In children, boosted protease inhibitors seem to be more forgiving of poor adherence than do nonnucleoside reverse-transcriptase inhibitors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Retroviral Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active / methods*
  • Child
  • Child, Preschool
  • HIV Infections / drug therapy*
  • HIV Protease Inhibitors / therapeutic use*
  • Humans
  • Infant
  • Patient Compliance*
  • Reverse Transcriptase Inhibitors / therapeutic use*
  • South Africa
  • Treatment Outcome
  • Viral Load

Substances

  • Anti-Retroviral Agents
  • HIV Protease Inhibitors
  • Reverse Transcriptase Inhibitors